FOSCARNET SODIUM
ANTIVIRAL - CMV INFECTION · CMV RETINITIS IN AIDS PATIENT ·+1
FRESENIUS KABI
Drug class
Antiviral - CMV Infection
The classification phrase "Antiviral - CMV Infection" is an administrative and compendial formulary category rather than a single pharmacologic drug class, encompassing distinct antiviral agents indicated for the prevention and treatment of cytomegalovirus disease. Read more about Antiviral - CMV Infection
40 drugs in this class 34 manufacturers
Drugs in Antiviral - CMV Infection
GANCICLOVIR SODIUM
ANTIVIRAL - CMV INFECTION · PREVENTION OF CMV DISEASE AFTER ORGAN TRANSPLANT ·+2
FRESENIUS KABI
FOSCARNET SODIUM
ANTIVIRAL - CMV INFECTION · CMV RETINITIS IN AIDS PATIENT ·+1
CAPLIN STERILES
FOSCARNET SODIUM
ANTIVIRAL - CMV INFECTION · CMV RETINITIS IN AIDS PATIENT ·+1
Pfizer Laboratories
Filter & compare in the drug finder →
Opens the drug finder with Antiviral - CMV Infection preselected. Add indication or manufacturer filters there.
The classification phrase "Antiviral - CMV Infection" is an administrative and compendial formulary category rather than a single pharmacologic drug class, encompassing distinct antiviral agents indicated for the prevention and treatment of cytomegalovirus disease.
Members of this category include viral DNA polymerase inhibitors such as ganciclovir, valganciclovir, foscarnet, and cidofovir, as well as newer targeted therapies like the terminase inhibitor letermovir and the protein kinase pUL97 inhibitor maribavir.
These medications function by selectively disrupting viral replication, DNA packaging, or capsid assembly.
Clinically, they are primarily deployed to manage CMV viremia and tissue-invasive disease in solid organ and hematopoietic stem cell transplant recipients, treat CMV retinitis in immunocompromised individuals with HIV/AIDS, and manage congenital infections.
-
fda.gov
The classification phrase "Antiviral - CMV Infection" is an administrative and compendial formulary category rather than a single pharmacologic drug class, encompassing distinct antiviral agents indicated for the prevention and treatment of cytomegalovirus disease Clinically, they are primarily deployed to manage CMV viremia and tissue-invasive disease in solid organ and hematopoietic stem cell transplant recipients, treat CMV retinitis in immunocompromised individuals with HIV/AIDS, and manage ...
-
connectrx.com
The classification phrase "Antiviral - CMV Infection" is an administrative and compendial formulary category rather than a single pharmacologic drug class, encompassing distinct antiviral agents indicated for the prevention and treatment of cytomegalovirus disease
-
nih.gov
The classification phrase "Antiviral - CMV Infection" is an administrative and compendial formulary category rather than a single pharmacologic drug class, encompassing distinct antiviral agents indicated for the prevention and treatment of cytomegalovirus disease
-
fda.gov
Members of this category include viral DNA polymerase inhibitors such as ganciclovir, valganciclovir, foscarnet, and cidofovir, as well as newer targeted therapies like the terminase inhibitor letermovir and the protein kinase pUL97 inhibitor maribavir These medications function by selectively disrupting viral replication, DNA packaging, or capsid assembly
-
medicaldialogues.in
Members of this category include viral DNA polymerase inhibitors such as ganciclovir, valganciclovir, foscarnet, and cidofovir, as well as newer targeted therapies like the terminase inhibitor letermovir and the protein kinase pUL97 inhibitor maribavir These medications function by selectively disrupting viral replication, DNA packaging, or capsid assembly
-
nih.gov
Members of this category include viral DNA polymerase inhibitors such as ganciclovir, valganciclovir, foscarnet, and cidofovir, as well as newer targeted therapies like the terminase inhibitor letermovir and the protein kinase pUL97 inhibitor maribavir These medications function by selectively disrupting viral replication, DNA packaging, or capsid assembly
-
fda.gov
Clinically, they are primarily deployed to manage CMV viremia and tissue-invasive disease in solid organ and hematopoietic stem cell transplant recipients, treat CMV retinitis in immunocompromised individuals with HIV/AIDS, and manage congenital infections
-
nih.gov
Clinically, they are primarily deployed to manage CMV viremia and tissue-invasive disease in solid organ and hematopoietic stem cell transplant recipients, treat CMV retinitis in immunocompromised individuals with HIV/AIDS, and manage congenital infections
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.